» Articles » PMID: 26430088

Risk Stratification for Rejection and Infection After Kidney Transplantation

Overview
Specialty Nephrology
Date 2015 Oct 3
PMID 26430088
Citations 33
Authors
Affiliations
Soon will be listed here.
Abstract

Background And Objectives: Definition of individual risk profile is the first step to implement strategies to keep the delicate balance between under- and overimmunosuppression after kidney transplantation.

Design, Setting, Participants, & Measurements: We used data from the Efficacy Limiting Toxicity Elimination Symphony Study (1190 patients between 2002 and 2004) to model risk of rejection and infection in the first year after kidney transplantation. External validation was performed in a study population from the Fixed-Dose Concentration-Controlled Trial (630 patients between 2003 and 2006).

Results: Despite different temporal dynamics, rejections and severe infections had similar overall incidences in the first year after transplantation (23.4% and 25.5%, respectively), and infections were the principal cause of death (43.2% of all deaths). Recipient older age, deceased donor, higher number of HLA mismatches, and high risk for cytomegalovirus disease were associated with infection; deceased donor, higher number of HLA mismatches, and immunosuppressive therapy including cyclosporin A (compared with tacrolimus), with rejection. These factors were integrated into a two-dimensional risk stratification model, which defined four risk groups: low risk for infection and rejection (30.8%), isolated risk for rejection (36.1%), isolated risk for infection (7.0%), and high risk for infection and rejection (26.1%). In internal validation, this model significantly discriminated the subgroups in terms of composite end point (low risk for infection/rejection, 24.4%; isolated risk for rejection and isolated risk for infection, 31.3%; high risk for infection/rejection, 54.4%; P<0.001), rejection episodes (isolated risk for infection and low risk for infection/rejection, 13.0%; isolated risk for rejection and high risk for infection/rejection, 24.2%; P=0.001), and infection episodes (low risk for infection/rejection and isolated risk for rejection, 12.0%; isolated risk for infection and high risk for infection/rejection, 37.6%; P<0.001). External validation confirmed the applicability of the model to an independent cohort.

Conclusions: We propose a two-dimensional risk stratification model able to disentangle the individual risk for rejection and infection in the first year after kidney transplantation. This concept can be applied to implement a personalized immunosuppressive and antimicrobial treatment approach.

Citing Articles

Donor hepatitis C status is not associated with an increased risk of acute rejection in kidney transplantation.

Johnson J, Engebretsen T, Mujtaba M, Stevenson H, Kulkarni R, Lea A Surg Pract Sci. 2025; 16():100236.

PMID: 39845340 PMC: 11749424. DOI: 10.1016/j.sipas.2024.100236.


The role of metagenomic next-generation sequencing in diagnosing and managing post-kidney transplantation infections.

Wu H, Cao H, Gao X, Shi C, Wang L, Gao B Front Cell Infect Microbiol. 2025; 14():1473068.

PMID: 39839264 PMC: 11747774. DOI: 10.3389/fcimb.2024.1473068.


Current and emerging tools for simultaneous assessment of infection and rejection risk in transplantation.

Tharmaraj D, Mulley W, Dendle C Front Immunol. 2024; 15:1490472.

PMID: 39660122 PMC: 11628869. DOI: 10.3389/fimmu.2024.1490472.


Precision in Immune Management: Balancing Steroid Exposure, Rejection Risk, and Infectious Outcomes in Adult Kidney Transplant Recipients.

Koi A, Johnson J, Engebretsen T, Mujtaba M, Lea A, Stevenson H J Pers Med. 2024; 14(11).

PMID: 39590598 PMC: 11595447. DOI: 10.3390/jpm14111106.


Assessing Long-Term Adverse Outcomes in Older Kidney Transplant Recipients: A Propensity Score-Matched Comparison of Early Steroid Withdrawal Versus Continuous Steroid Immunosuppression Using a Large Real-World Database.

Johnson J, Malik M, Engebretsen T, Mujtaba M, Lea A, Stevenson H Drugs Aging. 2024; 41(11):915-927.

PMID: 39417973 DOI: 10.1007/s40266-024-01147-4.


References
1.
Ekberg H, Tedesco-Silva H, Demirbas A, Vitko S, Nashan B, Gurkan A . Reduced exposure to calcineurin inhibitors in renal transplantation. N Engl J Med. 2007; 357(25):2562-75. DOI: 10.1056/NEJMoa067411. View

2.
Fishman J, Issa N . Infection in organ transplantation: risk factors and evolving patterns of infection. Infect Dis Clin North Am. 2010; 24(2):273-83. DOI: 10.1016/j.idc.2010.01.005. View

3.
Pascual M, Theruvath T, Kawai T, Tolkoff-Rubin N, Cosimi A . Strategies to improve long-term outcomes after renal transplantation. N Engl J Med. 2002; 346(8):580-90. DOI: 10.1056/NEJMra011295. View

4.
Naesens M, Sarwal M . Molecular diagnostics in transplantation. Nat Rev Nephrol. 2010; 6(10):614-28. DOI: 10.1038/nrneph.2010.113. View

5.
Meier-Kriesche H, Kaplan B . Immunosuppression in elderly renal transplant recipients: are current regimens too aggressive?. Drugs Aging. 2001; 18(10):751-9. DOI: 10.2165/00002512-200118100-00004. View